Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Σάββατο 25 Μαρτίου 2017

Persistent blood glucose reduction upon repeated transcranial electric stimulation in men

S1935861X.gif

Publication date: Available online 25 March 2017
Source:Brain Stimulation
Author(s): Alina Kistenmacher, Sebastian Manneck, Ewelina K. Wardzinski, Jan C. Martens, Georg Gohla, Uwe H. Melchert, Kamila Jauch-Chara, Kerstin M. Oltmanns
BackgroundTranscranial direct current stimulation (tDCS) of the human brain increases systemic glucose tolerance.Objective/HypothesisTo investigate whether this effect persists after one week of repeated stimulation. Because systemic glucose uptake relates to brain energy homeostasis, we concomitantly measured cerebral high-energy phosphate metabolites.MethodsIn a sham-controlled crossover design, 14 healthy men were tested under daily anodal tDCS vs. sham for 8 days. Systemic glucose metabolism was examined by concentrations of circulating glucose and insulin. Cerebral energy metabolism – i.e. adenosine triphosphate (ATP) and phosphocreatine (PCr) levels – was assessed by 31phosphorous magnetic resonance spectroscopy.ResultsBlood glucose concentrations were distinctly lower upon tDCS compared with sham stimulation on day 1. This effect persisted on day 8, while serum insulin levels remained persistently unchanged. Transcranial stimulation increased mean levels of ATP and PCr compared with sham on day 1 only. Blood glucose concentrations negatively correlated with PCr content after repeated daily stimulation.ConclusionsOur data confirm that tDCS reduces blood glucose through an insulin-independent mechanism. This effect persists after 8 days of repeated stimulation and relates to brain energy metabolism. Therefore, transcranial electric stimulation may be a promising non-pharmacological adjuvant option to treat systemic disorders such as glucose intolerance or type 2 diabetes mellitus with a low side-effect profile.



http://ift.tt/2nhCb82

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου